Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.41 |
| ▸ | ATF1 | P18846 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627995 | 0.87 | CES2 (0.67) | CES2GAADHODHATF1NFKB1 | |
| SCHEMBL7188717 | 0.86 | CES2 (0.54) | CES2GAATSHRMAPK1PTGS1 | |
| Hydrochloric Acid SCHEMBL4027010 | 0.85 | CES2 (0.64) | CES2GAADHODHATF1NFKB1 | |
| Hydrochloric Acid SCHEMBL4372326 | 0.85 | CES2 (0.64) | CES2GAADHODHATF1NFKB1 | |
| SCHEMBL787785 | 0.84 | CES2 (0.52) | CES2GAADHODHTSHRMAPK1 | |
| SCHEMBL29451089 | 0.84 | CES2 (0.52) | CES2GAADHODHTSHRMAPK1 | |
| SCHEMBL4974165 | 0.82 | CES2 (0.50) | CES2GAATSHRMAPK1PTGS1 | |
| SCHEMBL628456 | 0.80 | CES2 (0.52) | CES2GAADHODHATF1NFKB1 | |
| SCHEMBL2452507 | 0.80 | CES2 (0.52) | CES2GAADHODHPTGS1ATF1 | |
| SCHEMBL17048542 | 0.80 | CES2 (0.57) | CES2GAADHODHRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| CN-101291917-A | Diaryl urea derivatives for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2008-10-22 | — | — | CN | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-1551842-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004035588-A1 | PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-0162806-B1 | AZO COMPOUNDS CONTAINING AT LEAST ONE CARBON AMIDE GROUP | CIBA-GEIGY AG (CH) | 1989-01-25 | — | — | EP | disclosed |
| US-4737581-A | PIGMENTING HIGH-MOLECULAR-WEIGHT COMPOUNDS; PRINTING INKS; LACQUERS COLORFASTNESS; REDS AND ORANGES | CIBA-GEIGY CORPORATION (US) | 1988-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | CES2 3770/4885GAA 1771/4885DHODH 2166/4885 |
| US-20060069097-A1 | Pyradazine compounds as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | CES2 3872/4885GAA 2919/4885DHODH 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.